Shares of Depomed Inc (NASDAQ:DEPO) have been given an average rating of “Hold” by the thirteen analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $10.72.
Several equities research analysts have commented on DEPO shares. Mizuho raised shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Tuesday, December 5th. ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 5th. BidaskClub raised shares of Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Piper Jaffray Companies reissued a “hold” rating and set a $9.00 price target on shares of Depomed in a research report on Thursday, December 7th. Finally, Royal Bank of Canada set a $9.00 price target on shares of Depomed and gave the stock a “hold” rating in a research report on Thursday, December 7th.
In related news, SVP Matthew M. Gosling sold 45,519 shares of the company’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $6.58, for a total value of $299,515.02. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Arthur J. Higgins purchased 75,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The stock was bought at an average price of $8.16 per share, for a total transaction of $612,000.00. The disclosure for this purchase can be found here. 2.59% of the stock is currently owned by corporate insiders.
Depomed (NASDAQ:DEPO) traded up $0.12 on Tuesday, reaching $6.95. 846,399 shares of the company traded hands, compared to its average volume of 1,404,198. The company has a market cap of $440.63, a PE ratio of -4.26 and a beta of 1.10. Depomed has a 1-year low of $4.31 and a 1-year high of $16.29. The company has a quick ratio of 0.70, a current ratio of 0.74 and a debt-to-equity ratio of 3.21.
Depomed (NASDAQ:DEPO) last posted its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.10 by $0.05. Depomed had a negative net margin of 26.92% and a negative return on equity of 45.19%. The business had revenue of $94.41 million for the quarter, compared to analysts’ expectations of $88.75 million. equities research analysts predict that Depomed will post -0.89 EPS for the current fiscal year.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.